Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

December 5, 2019

Exploring the Link Between Infertility and Prostate Cancer

Author(s):

Tom Castles

New research suggests men with infertility could face a 30% to 60% higher risk of prostate cancer.

Men with infertility who undergo assisted reproduction are at increased risk of being diagnosed with prostate cancer and are more likely to be diagnosed at a younger age, according to new research published in the British Medical Journal.

Results were pulled from a study conducted in Sweden between 1994 and 2014. Researchers included data from more than 1.1 million fathers, who were grouped according to their fertility status by mode of conception — 20,618 by in vitro fertilization (IVF), 14,882 by intra-cytoplasmic sperm injection (ICSI) and 1,145,990 by natural conception.

Fathers who used ICSI had a 60% higher risk and those who used IVF had a 30% higher risk of being diagnosed with prostate cancer than men who conceived naturally. Their increased risk was most pronounced before the age of 55.

Despite the fact that men who underwent assisted reproduction saw an increased risk, it is important to note that overall prostate cancer risk remained below half of one percent across the study’s three groups. While men who conceived naturally were diagnosed at a rate of 0.28%, men who conceived by ICSI were diagnosed at a rate of 0.42%, and 0.37% of men who conceived through IVF received diagnoses.

It’s also important to note that this is not the first study to investigate a link between prostate cancer and infertility. Three American studies have reported an increased risk of prostate cancer in men with impaired semen quality, corroborating evidence found in this study in the BMJ.

However, three Scandinavian studies and one American study indicated a lower risk of prostate cancer in childless men, and these findings were confirmed in a follow up meta-analysis that summarized evidence from 10 relevant studies. Still other research found no discernible relation between fatherhood and the risk of prostate cancer.

Still, evidence from this study in the BMJ is noteworthy because of its large sample size, which contains virtually all men who fathered a child in Sweden over the course of 20 years.

“For many people having children is an important aspect of life. Yet as many as 15 to 20% of all couples struggle to conceive naturally,” wrote Yahia Al-Jebari, the study’s lead author, in an accompanying editorial statement. “One of the solutions available for couples is to go through assisted reproduction. It is understandable that healthcare providers and patients only focus on what they consider to be the main aim — to have a baby. However, the struggle to conceive has been shown to be associated with a multitude of future morbidities among men, ranging from metabolic syndrome to autoimmune disease.”

Because of the strength of their findings, the authors wrote that they believe that the risk of prostate cancer is “inherent to male fertility itself, regardless of the fertility treatment type.” As a result, preventative measures should be extended from only men who are undergoing assisted reproduction to all men who are experiencing infertility.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of thumbnail.
Image of Dr. Deville.
Image of Doctor.
Image of Dr. Tagawa.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Image of man with black hair.
Related Content
Advertisement
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
June 7th 2025

Utilizing AI in Prostate Cancer Care and Management

Alex Biese
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Dr. Alicia Morgans discussed complications associated with androgen deprivation therapy in prostate cancer: © stock.adobe.com.
June 4th 2025

Addressing Complications from ADT Therapy to Treat Prostate Cancer

Kristie L. Kahl
Dr. Alicia Morgans discussed complications associated with ADT in prostate cancer, and how men can still maintain quality of life regardless.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.
June 3rd 2025

FDA Approves Nubeqa in Metastatic Castration-Sensitive Prostate Cancer

Spencer Feldman
The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.
Image of man
June 3rd 2025

Akeega Combo Delays Progression in HRR+ Castration-Sensitive Prostate Cancer

Silas Inman
Akeega delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations.
Related Content
Advertisement
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
June 7th 2025

Utilizing AI in Prostate Cancer Care and Management

Alex Biese
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Dr. Alicia Morgans discussed complications associated with androgen deprivation therapy in prostate cancer: © stock.adobe.com.
June 4th 2025

Addressing Complications from ADT Therapy to Treat Prostate Cancer

Kristie L. Kahl
Dr. Alicia Morgans discussed complications associated with ADT in prostate cancer, and how men can still maintain quality of life regardless.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.
June 3rd 2025

FDA Approves Nubeqa in Metastatic Castration-Sensitive Prostate Cancer

Spencer Feldman
The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.
Image of man
June 3rd 2025

Akeega Combo Delays Progression in HRR+ Castration-Sensitive Prostate Cancer

Silas Inman
Akeega delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.